Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

11/14/24 1:28:29 PM ET

Precision Instruments

Health Care

Get the next $NEO alert in real time by email

SC 13G/A 1 neo13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NEOGENOMICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64049M209 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 6,541,400 6. Shared Voting Power* 0 7. Sole Dispositive Power* 6,541,400 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,541,400 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: NEOGENOMICS INC Item 1(b) Address of Issuer's Principal Executive Offices: 9490 NEOGENOMICS WAY, FORT MYERS, FLORIDA 33912 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 64049M209 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $NEO alert in real time by email

Recent Analyst Ratings for

$NEO

Date	Price Target	Rating	Analyst
4/29/2026	$25.00	Market Perform → Outperform	Leerink Partners
7/30/2025		Buy → Neutral	BTIG Research
7/29/2025		Outperform → Mkt Perform	William Blair
5/15/2025		Neutral	Guggenheim
4/30/2025	$9.00	Outperform → Market Perform	Leerink Partners
1/13/2025		Buy → Hold	The Benchmark Company
12/10/2024	$22.00	Buy	Jefferies
5/1/2024	$26.00	Buy	Craig Hallum

More analyst ratings

Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

11/14/24 1:28:29 PM ET

$NEO

Precision Instruments

Health Care

Get the next $NEO alert in real time by email

Recent Analyst Ratings for

$NEO

Date	Price Target	Rating	Analyst
4/29/2026	$25.00	Market Perform → Outperform	Leerink Partners
7/30/2025		Buy → Neutral	BTIG Research
7/29/2025		Outperform → Mkt Perform	William Blair
5/15/2025		Neutral	Guggenheim
4/30/2025	$9.00	Outperform → Market Perform	Leerink Partners
1/13/2025		Buy → Hold	The Benchmark Company
12/10/2024	$22.00	Buy	Jefferies
5/1/2024	$26.00	Buy	Craig Hallum

More analyst ratings

Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NEO

Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NEO

$NEO
SEC Filings

NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by NeoGenomics Inc.

SEC Form SCHEDULE 13G filed by NeoGenomics Inc.

$NEO
Press Releases

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Reports First Quarter 2026 Results

$NEO
Analyst Ratings

NeoGenomics upgraded by Leerink Partners with a new price target

NeoGenomics downgraded by BTIG Research

NeoGenomics downgraded by William Blair

$NEO
Insider Trading

Director Kenny John P. converted options into 5,893 shares (SEC Form 4)

Director Williams Felicia converted options into 23,077 shares, increasing direct ownership by 322% to 30,237 units (SEC Form 4)

Director Tetrault Lynn A. converted options into 23,077 shares, increasing direct ownership by 31% to 96,729 units (SEC Form 4)

$NEO
Insider Purchases

Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

$NEO
Leadership Updates

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

$NEO
Financials

NeoGenomics Reports First Quarter 2026 Results

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

$NEO
Large Ownership Changes